JP2009516529A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009516529A5 JP2009516529A5 JP2008542449A JP2008542449A JP2009516529A5 JP 2009516529 A5 JP2009516529 A5 JP 2009516529A5 JP 2008542449 A JP2008542449 A JP 2008542449A JP 2008542449 A JP2008542449 A JP 2008542449A JP 2009516529 A5 JP2009516529 A5 JP 2009516529A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition
- sequence
- polynucleotide
- norovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 62
- 108091033319 polynucleotide Proteins 0.000 claims 46
- 239000002157 polynucleotide Substances 0.000 claims 46
- 102000040430 polynucleotide Human genes 0.000 claims 46
- 229920001184 polypeptide Polymers 0.000 claims 38
- 108090000765 processed proteins & peptides Proteins 0.000 claims 38
- 102000004196 processed proteins & peptides Human genes 0.000 claims 38
- 241001263478 Norovirus Species 0.000 claims 31
- 241000369757 Sapovirus Species 0.000 claims 28
- 238000000034 method Methods 0.000 claims 16
- 230000002163 immunogen Effects 0.000 claims 13
- 241000714209 Norwalk virus Species 0.000 claims 12
- 239000002671 adjuvant Substances 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 230000028993 immune response Effects 0.000 claims 11
- 241001466963 Hawaii calicivirus Species 0.000 claims 8
- 241000509413 Snow Mountain virus Species 0.000 claims 8
- 239000002245 particle Substances 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 7
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 claims 7
- 101710130262 Probable Vpr-like protein Proteins 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 7
- 239000013604 expression vector Substances 0.000 claims 5
- 241000700605 Viruses Species 0.000 claims 4
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 102000037865 fusion proteins Human genes 0.000 claims 4
- 108090000565 Capsid Proteins Proteins 0.000 claims 3
- 102100023321 Ceruloplasmin Human genes 0.000 claims 3
- 241000588724 Escherichia coli Species 0.000 claims 3
- 101710172711 Structural protein Proteins 0.000 claims 3
- 210000000234 capsid Anatomy 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 239000003053 toxin Substances 0.000 claims 3
- 231100000765 toxin Toxicity 0.000 claims 3
- 230000001131 transforming effect Effects 0.000 claims 3
- 101000768957 Acholeplasma phage L2 Uncharacterized 37.2 kDa protein Proteins 0.000 claims 2
- 101000823746 Acidianus ambivalens Uncharacterized 17.7 kDa protein in bps2 3'region Proteins 0.000 claims 2
- 101000916369 Acidianus ambivalens Uncharacterized protein in sor 5'region Proteins 0.000 claims 2
- 101000769342 Acinetobacter guillouiae Uncharacterized protein in rpoN-murA intergenic region Proteins 0.000 claims 2
- 101000823696 Actinobacillus pleuropneumoniae Uncharacterized glycosyltransferase in aroQ 3'region Proteins 0.000 claims 2
- 101000786513 Agrobacterium tumefaciens (strain 15955) Uncharacterized protein outside the virF region Proteins 0.000 claims 2
- 101000618005 Alkalihalobacillus pseudofirmus (strain ATCC BAA-2126 / JCM 17055 / OF4) Uncharacterized protein BpOF4_00885 Proteins 0.000 claims 2
- 102100034044 All-trans-retinol dehydrogenase [NAD(+)] ADH1B Human genes 0.000 claims 2
- 101710193111 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 claims 2
- 102100020724 Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Human genes 0.000 claims 2
- 101000967489 Azorhizobium caulinodans (strain ATCC 43989 / DSM 5975 / JCM 20966 / LMG 6465 / NBRC 14845 / NCIMB 13405 / ORS 571) Uncharacterized protein AZC_3924 Proteins 0.000 claims 2
- 101000823761 Bacillus licheniformis Uncharacterized 9.4 kDa protein in flaL 3'region Proteins 0.000 claims 2
- 101000819719 Bacillus methanolicus Uncharacterized N-acetyltransferase in lysA 3'region Proteins 0.000 claims 2
- 101000789586 Bacillus subtilis (strain 168) UPF0702 transmembrane protein YkjA Proteins 0.000 claims 2
- 101000792624 Bacillus subtilis (strain 168) Uncharacterized protein YbxH Proteins 0.000 claims 2
- 101000790792 Bacillus subtilis (strain 168) Uncharacterized protein YckC Proteins 0.000 claims 2
- 101000819705 Bacillus subtilis (strain 168) Uncharacterized protein YlxR Proteins 0.000 claims 2
- 101000948218 Bacillus subtilis (strain 168) Uncharacterized protein YtxJ Proteins 0.000 claims 2
- 101000718627 Bacillus thuringiensis subsp. kurstaki Putative RNA polymerase sigma-G factor Proteins 0.000 claims 2
- 101000641200 Bombyx mori densovirus Putative non-structural protein Proteins 0.000 claims 2
- 101000947633 Claviceps purpurea Uncharacterized 13.8 kDa protein Proteins 0.000 claims 2
- 101000948901 Enterobacteria phage T4 Uncharacterized 16.0 kDa protein in segB-ipI intergenic region Proteins 0.000 claims 2
- 101000805958 Equine herpesvirus 4 (strain 1942) Virion protein US10 homolog Proteins 0.000 claims 2
- 101000790442 Escherichia coli Insertion element IS2 uncharacterized 11.1 kDa protein Proteins 0.000 claims 2
- 101000788354 Escherichia phage P2 Uncharacterized 8.2 kDa protein in gpA 5'region Proteins 0.000 claims 2
- 101000770304 Frankia alni UPF0460 protein in nifX-nifW intergenic region Proteins 0.000 claims 2
- 101000797344 Geobacillus stearothermophilus Putative tRNA (cytidine(34)-2'-O)-methyltransferase Proteins 0.000 claims 2
- 101000748410 Geobacillus stearothermophilus Uncharacterized protein in fumA 3'region Proteins 0.000 claims 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims 2
- 101000772675 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) UPF0438 protein HI_0847 Proteins 0.000 claims 2
- 101000631019 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Uncharacterized protein HI_0350 Proteins 0.000 claims 2
- 101000768938 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 8.9 kDa protein in int-C1 intergenic region Proteins 0.000 claims 2
- 101710121996 Hexon protein p72 Proteins 0.000 claims 2
- 101000785414 Homo sapiens Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Proteins 0.000 claims 2
- 101000833492 Homo sapiens Jouberin Proteins 0.000 claims 2
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 claims 2
- 102100024407 Jouberin Human genes 0.000 claims 2
- 101000782488 Junonia coenia densovirus (isolate pBRJ/1990) Putative non-structural protein NS2 Proteins 0.000 claims 2
- 101000811523 Klebsiella pneumoniae Uncharacterized 55.8 kDa protein in cps region Proteins 0.000 claims 2
- 101000818409 Lactococcus lactis subsp. lactis Uncharacterized HTH-type transcriptional regulator in lacX 3'region Proteins 0.000 claims 2
- 101000878851 Leptolyngbya boryana Putative Fe(2+) transport protein A Proteins 0.000 claims 2
- 101710125418 Major capsid protein Proteins 0.000 claims 2
- 101000758828 Methanosarcina barkeri (strain Fusaro / DSM 804) Uncharacterized protein Mbar_A1602 Proteins 0.000 claims 2
- 101001122401 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF3 Proteins 0.000 claims 2
- 101001055788 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) Pentapeptide repeat protein MfpA Proteins 0.000 claims 2
- 101000740670 Orgyia pseudotsugata multicapsid polyhedrosis virus Protein C42 Proteins 0.000 claims 2
- 101000769182 Photorhabdus luminescens Uncharacterized protein in pnp 3'region Proteins 0.000 claims 2
- 101000961392 Pseudescherichia vulneris Uncharacterized 29.9 kDa protein in crtE 3'region Proteins 0.000 claims 2
- 101000731030 Pseudomonas oleovorans Poly(3-hydroxyalkanoate) polymerase 2 Proteins 0.000 claims 2
- 101001065485 Pseudomonas putida Probable fatty acid methyltransferase Proteins 0.000 claims 2
- 101000711023 Rhizobium leguminosarum bv. trifolii Uncharacterized protein in tfuA 3'region Proteins 0.000 claims 2
- 101000948156 Rhodococcus erythropolis Uncharacterized 47.3 kDa protein in thcA 5'region Proteins 0.000 claims 2
- 101000917565 Rhodococcus fascians Uncharacterized 33.6 kDa protein in fasciation locus Proteins 0.000 claims 2
- 101000790284 Saimiriine herpesvirus 2 (strain 488) Uncharacterized 9.5 kDa protein in DHFR 3'region Proteins 0.000 claims 2
- 101000936719 Streptococcus gordonii Accessory Sec system protein Asp3 Proteins 0.000 claims 2
- 101000788499 Streptomyces coelicolor Uncharacterized oxidoreductase in mprA 5'region Proteins 0.000 claims 2
- 101001102841 Streptomyces griseus Purine nucleoside phosphorylase ORF3 Proteins 0.000 claims 2
- 101000708557 Streptomyces lincolnensis Uncharacterized 17.2 kDa protein in melC2-rnhH intergenic region Proteins 0.000 claims 2
- 101000649826 Thermotoga neapolitana Putative anti-sigma factor antagonist TM1081 homolog Proteins 0.000 claims 2
- 101000827562 Vibrio alginolyticus Uncharacterized protein in proC 3'region Proteins 0.000 claims 2
- 101000778915 Vibrio parahaemolyticus serotype O3:K6 (strain RIMD 2210633) Uncharacterized membrane protein VP2115 Proteins 0.000 claims 2
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 claims 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 239000011859 microparticle Substances 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 101000787132 Acidithiobacillus ferridurans Uncharacterized 8.2 kDa protein in mobL 3'region Proteins 0.000 claims 1
- 101000827262 Acidithiobacillus ferrooxidans Uncharacterized 18.9 kDa protein in mobE 3'region Proteins 0.000 claims 1
- 241000710929 Alphavirus Species 0.000 claims 1
- 101000811747 Antithamnion sp. UPF0051 protein in atpA 3'region Proteins 0.000 claims 1
- 101000827607 Bacillus phage SPP1 Uncharacterized 8.5 kDa protein in GP2-GP6 intergenic region Proteins 0.000 claims 1
- 101000961975 Bacillus thuringiensis Uncharacterized 13.4 kDa protein Proteins 0.000 claims 1
- 101000964407 Caldicellulosiruptor saccharolyticus Uncharacterized 10.7 kDa protein in xynB 3'region Proteins 0.000 claims 1
- 208000006339 Caliciviridae Infections Diseases 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 101000768777 Haloferax lucentense (strain DSM 14919 / JCM 9276 / NCIMB 13854 / Aa 2.2) Uncharacterized 50.6 kDa protein in the 5'region of gyrA and gyrB Proteins 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 101000607404 Infectious laryngotracheitis virus (strain Thorne V882) Protein UL24 homolog Proteins 0.000 claims 1
- 101000735632 Klebsiella pneumoniae Uncharacterized 8.8 kDa protein in aacA4 3'region Proteins 0.000 claims 1
- 229920001244 Poly(D,L-lactide) Polymers 0.000 claims 1
- 108010076039 Polyproteins Proteins 0.000 claims 1
- 241000702670 Rotavirus Species 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 241000754835 Sapovirus isolates Species 0.000 claims 1
- 101000818100 Spirochaeta aurantia Uncharacterized 12.7 kDa protein in trpE 5'region Proteins 0.000 claims 1
- 101001037658 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) Glucokinase Proteins 0.000 claims 1
- 101001120268 Streptomyces griseus Protein Y Proteins 0.000 claims 1
- 229940037003 alum Drugs 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000010419 fine particle Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001432 poly(L-lactide) Polymers 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73921705P | 2005-11-22 | 2005-11-22 | |
| US60/739,217 | 2005-11-22 | ||
| PCT/US2006/045280 WO2007081447A2 (en) | 2005-11-22 | 2006-11-22 | Norovirus and sapovirus antigens |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009516529A JP2009516529A (ja) | 2009-04-23 |
| JP2009516529A5 true JP2009516529A5 (enExample) | 2011-01-13 |
| JP5215865B2 JP5215865B2 (ja) | 2013-06-19 |
Family
ID=38256776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008542449A Active JP5215865B2 (ja) | 2005-11-22 | 2006-11-22 | ノロウイルス抗原およびサポウイルス抗原 |
Country Status (7)
| Country | Link |
|---|---|
| US (7) | US7527801B2 (enExample) |
| EP (2) | EP1969001A2 (enExample) |
| JP (1) | JP5215865B2 (enExample) |
| AU (1) | AU2006335256B2 (enExample) |
| CA (1) | CA2630220C (enExample) |
| ES (1) | ES2514316T3 (enExample) |
| WO (1) | WO2007081447A2 (enExample) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL154853A0 (en) * | 2000-10-27 | 2003-10-31 | Chiron Spa | Nucleic acids and proteins from streptococcus groups a & b |
| US20040235770A1 (en) * | 2003-04-02 | 2004-11-25 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations and related methods of use |
| CA2630220C (en) | 2005-11-22 | 2020-10-13 | Doris Coit | Norovirus and sapovirus antigens |
| CN103873202B (zh) | 2006-07-12 | 2018-03-13 | 英特尔公司 | 确定可预测的调制和编码方案的系统和方法 |
| AU2014200084B2 (en) * | 2006-09-29 | 2016-07-28 | Takeda Vaccines, Inc. | Method of conferring a protective immune response to norovirus |
| DK2601969T3 (en) | 2006-09-29 | 2016-04-18 | Takeda Vaccines Inc | Norovirus vaccine formulations |
| KR101576219B1 (ko) * | 2007-03-14 | 2015-12-10 | 다케다 백신즈 인코포레이티드 | 바이러스 유사 입자 정제 |
| US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
| CA2615372A1 (en) | 2007-07-13 | 2009-01-13 | Marc-Andre D'aoust | Influenza virus-like particles (vlps) comprising hemagglutinin |
| US7608256B2 (en) | 2007-09-12 | 2009-10-27 | Aeras Global Tb Vaccine Foundation | Methods to increase transgene expression from bacterial-based delivery systems by co-expressing suppressors of the eukaryotic type I interferon response |
| US20100266636A1 (en) * | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
| SG184733A1 (en) * | 2007-09-18 | 2012-10-30 | Ligocyte Pharmaceuticals Inc | Method of conferring a protective immune response to norovirus |
| US20110020786A1 (en) * | 2007-10-08 | 2011-01-27 | Baylor College Of Medicine | Peptide dendrimers: affinity reagents for binding noroviruses |
| JP2011503104A (ja) | 2007-11-09 | 2011-01-27 | カリフォルニア インスティテュート オブ テクノロジー | 免疫調節化合物ならびに関連組成物および方法 |
| WO2009082594A2 (en) | 2007-11-26 | 2009-07-02 | Fox Chase Cancer Center | Secreted/cell bound poxvirus proteins and methods of use thereof as vaccines and anti-viral agents |
| CN103122354B (zh) | 2007-11-27 | 2018-03-23 | 麦迪卡格公司 | 表达血凝素之转基因植物中生产的重组流感病毒样颗粒(vlp) |
| ES2712505T3 (es) | 2008-04-17 | 2019-05-13 | Pds Biotechnology Corp | Estimulación de una respuesta inmunitaria por enantiómeros de lípidos catiónicos |
| CA2733589C (en) * | 2008-08-08 | 2021-07-13 | Ligocyte Pharmaceuticals, Inc. | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
| US20120021405A1 (en) * | 2009-01-26 | 2012-01-26 | Baylor College Of Medicine | Single Chain Antibody for the Detection of Noroviruses |
| US20110070260A1 (en) * | 2009-09-09 | 2011-03-24 | Baric Ralph S | Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use |
| BR112012006414B1 (pt) * | 2009-09-22 | 2020-09-15 | Medicago Inc | Métodos para preparação de proteínas derivadas de plantas |
| ES2694100T3 (es) * | 2010-04-07 | 2018-12-18 | California Institute Of Technology | Vehículo para distribuir un compuesto en una membrana mucosa y composiciones, procedimientos y sistemas relacionados |
| JP2013529894A (ja) | 2010-04-07 | 2013-07-25 | ノバルティス アーゲー | パルボウイルスｂ１９のウイルス様粒子を生成するための方法 |
| WO2011136506A2 (ko) * | 2010-04-30 | 2011-11-03 | 중앙대학교 산학협력단 | 로타바이러스 나노입자를 이용한 재조합 복합 항원의 제조방법 |
| PT3243526T (pt) | 2010-07-06 | 2020-03-04 | Glaxosmithkline Biologicals Sa | Distribuição de arn para despoletar múltiplas vias imunitárias |
| WO2012006293A1 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Norovirus derived immunogenic compositions and methods |
| AU2011276234B2 (en) | 2010-07-06 | 2016-02-25 | Glaxosmithkline Biologicals S.A. | Liposomes with lipids having an advantageous pKa- value for RNA delivery |
| PL2591114T3 (pl) | 2010-07-06 | 2017-08-31 | Glaxosmithkline Biologicals Sa | Immunizacja dużych ssaków małymi dawkami rna |
| PT3981427T (pt) | 2010-08-31 | 2022-06-27 | Glaxosmithkline Biologicals Sa | Lipossomas peguilados para entrega de arn codificador de imunogénio |
| TR201903651T4 (tr) * | 2010-10-11 | 2019-04-22 | Glaxosmithkline Biologicals Sa | Antijen uygulama platformları. |
| FI122520B (fi) * | 2010-10-15 | 2012-03-15 | Vesna Blazevic | Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena |
| TWI620816B (zh) | 2011-03-23 | 2018-04-11 | 苜蓿股份有限公司 | 植物衍生蛋白回收方法 |
| EP2729165B1 (en) | 2011-07-06 | 2017-11-08 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| DK3299030T3 (da) | 2011-07-11 | 2022-09-05 | Takeda Vaccines Inc | Parenterale norovirus-vaccineformuleringer |
| US9539281B2 (en) | 2011-07-12 | 2017-01-10 | The Brigham And Women's Hospital, Inc. | Lipid-containing PSA compositions, methods of isolation and methods of use thereof |
| TWI673062B (zh) * | 2011-09-12 | 2019-10-01 | 美商Ｐｄｓ生技公司 | 粒狀疫苗調配物 |
| US9808517B2 (en) | 2012-04-06 | 2017-11-07 | Cornell University | Subunit vaccine delivery platform for robust humoral and cellular immune responses |
| KR102162118B1 (ko) * | 2012-05-11 | 2020-10-07 | 메디카고 인코포레이티드 | 식물에서 로타바이러스-유사 입자 생산 |
| CA2876656C (en) | 2012-06-15 | 2023-09-26 | Pds Biotechnology Corporation | Cationic lipid vaccine compositions and methods of use |
| JOP20130186B1 (ar) | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | تنقية الجزيئات الشبيهة بالفيروسات |
| US9732144B2 (en) * | 2012-07-05 | 2017-08-15 | Ohio State Innovation Foundation | Infectious bursal disease (IBDV) vaccine compositions |
| US10086062B2 (en) | 2012-07-05 | 2018-10-02 | Ohio State Innovation Foundation | Infectious pancreatic necrosis virus (IPNV) vaccine compositions |
| US20140017257A1 (en) * | 2012-07-11 | 2014-01-16 | Xi Jiang | IgY From Norovirus P Particles And Their Derivatives |
| TWI672149B (zh) | 2012-09-21 | 2019-09-21 | 美商Ｐｄｓ生技公司 | 改良之疫苗組成物及使用方法 |
| US9975923B2 (en) * | 2013-03-15 | 2018-05-22 | The University Of North Carolina At Chapel Hill | Methods and compositions for norovirus blockade epitopes |
| CN103243115A (zh) * | 2013-04-28 | 2013-08-14 | 集美大学 | 一种诺如病毒多表位抗原基因 |
| JP2015015931A (ja) * | 2013-07-12 | 2015-01-29 | 株式会社Ｕｍｎファーマ | ウイルス様粒子を含む培養物の製造方法 |
| WO2015104525A1 (en) | 2014-01-08 | 2015-07-16 | Vodafone Ip Licensing Limited | Telecommunications network with optimisation of content delivery |
| JP6841762B2 (ja) | 2015-01-23 | 2021-03-10 | メディカゴ インコーポレイテッド | 植物中でのロタウイルス様粒子産生 |
| US12060391B2 (en) * | 2015-03-16 | 2024-08-13 | The Broad Institute, Inc. | Constructs for continuous monitoring of live cells |
| WO2016201342A1 (en) | 2015-06-10 | 2016-12-15 | California Institute Of Technology | Sepsis treatment and related compositions methods and systems |
| CA2997211A1 (en) | 2015-08-19 | 2017-02-23 | President And Fellows Of Harvard College | Lipidated psa compositions and methods |
| US20180243397A1 (en) | 2015-08-28 | 2018-08-30 | Ron Cobb | Norovirus vaccine |
| EP3374496A4 (en) | 2015-11-13 | 2019-07-10 | PDS Biotechnology Corporation | LIPIDES AS SYNTHETIC VECTORS FOR IMPROVING ANTIGEN PROCESSING AND PRESENTATION EX-VIVO IN DENDRITIC CELL THERAPY |
| EP4477662A3 (en) * | 2016-05-04 | 2025-03-19 | CureVac SE | Nucleic acid molecules and uses thereof |
| WO2018014012A1 (en) | 2016-07-15 | 2018-01-18 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
| EP3530674B1 (en) | 2016-10-23 | 2024-04-24 | Denka Company Limited | Polypeptide monomer, associated product formed of said polypeptide monomer having cell penetration function, norovirus component vaccine for subcutaneous, intradermal, percutaneous or intramuscular administration and having said associated product as effective component thereof, and method for producing said associated product |
| CA3056812C (en) | 2017-03-23 | 2022-11-29 | Medicago Inc. | Norovirus fusion proteins and vlps comprising norovirus fusion proteins |
| WO2018182983A1 (en) | 2017-03-28 | 2018-10-04 | Children's Hospital Medical Center | Norovirus s particle based vaccines and methods of making and using same |
| WO2019079594A1 (en) * | 2017-10-18 | 2019-04-25 | The University Of North Carolina At Chapel Hill | METHODS AND COMPOSITIONS FOR VACCINES AGAINST NOVOVIRUS AND DIAGNOSIS OF NOVOVIRUS |
| EP3752185A1 (en) | 2018-02-15 | 2020-12-23 | Icon Genetics GmbH | Immunogenic composition and vaccine for generating an immune response to norovirus |
| EP3863668A1 (en) * | 2018-10-12 | 2021-08-18 | Deutsches Krebsforschungszentrum | Epstein-barr virus-like particles with broadened antigenic spectrum |
| AR117462A1 (es) * | 2018-12-20 | 2021-08-04 | Takeda Vaccines Inc | Vacuna contra norovirus, formulaciones y métodos |
| JP7527848B2 (ja) * | 2019-05-29 | 2024-08-05 | 花王株式会社 | ノロウイルス結合ペプチド |
| EP4087604A4 (en) * | 2020-01-08 | 2023-11-01 | Bharat Biotech International Limited | COMPOSITIONS OF VIRAL VACCINES AND THEIR PREPARATION METHODS |
| HRP20251116T1 (hr) | 2020-07-20 | 2025-11-21 | Enanta Pharmaceuticals, Inc. | Funkcionalizirani peptidi koji sadrže dva pirolidinska prstena kao antikoronavirusni agensi |
| US20230272351A1 (en) * | 2020-09-02 | 2023-08-31 | The Regents Of The University Of California | Covid assay controls |
| US20240009298A1 (en) * | 2020-09-03 | 2024-01-11 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
| US11352363B1 (en) | 2020-11-23 | 2022-06-07 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US11384090B2 (en) | 2020-11-23 | 2022-07-12 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| EP4247387A1 (en) | 2020-11-23 | 2023-09-27 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| CA3208643A1 (en) | 2021-01-18 | 2022-07-21 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
| WO2022235605A1 (en) | 2021-05-04 | 2022-11-10 | Enanta Pharmaceuticals, Inc. | Novel macrocyclic antiviral agents |
| US12398147B2 (en) | 2021-05-11 | 2025-08-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic spiropyrrolidine derived antiviral agents |
| US11319325B1 (en) | 2021-05-11 | 2022-05-03 | Enanta Pharmaceuticals, Inc. | Macrocyclic spiropyrrolidine derived antiviral agents |
| US20240238401A1 (en) * | 2021-05-21 | 2024-07-18 | Takeda Vaccines, Inc. | Solid composition, freeze-drying method and glass vial |
| EP4362975A4 (en) * | 2021-06-28 | 2025-05-14 | VST LLC dba Medgene Labs | SAPOVIRUS VACCINES |
| US11325916B1 (en) | 2021-07-29 | 2022-05-10 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US11339170B1 (en) | 2021-07-23 | 2022-05-24 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US12479854B2 (en) | 2021-07-29 | 2025-11-25 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| WO2023086350A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
| WO2023086400A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| WO2023086352A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| WO2023107419A1 (en) | 2021-12-08 | 2023-06-15 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
| US12145941B2 (en) | 2021-12-08 | 2024-11-19 | Enanta Pharmaceuticals, Inc. | Heterocyclic antiviral agents |
| US12145942B2 (en) | 2022-04-05 | 2024-11-19 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| WO2025064844A1 (en) * | 2023-09-20 | 2025-03-27 | Iowa State University Research Foundation, Inc. | Porcine sapovirus isolates and immunogenic compositions therefrom |
Family Cites Families (158)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US694286A (en) | 1901-09-30 | 1902-02-25 | James Kenney | Tap for ale-casks. |
| US4431739A (en) | 1979-11-05 | 1984-02-14 | Genentech, Inc. | Transformant bacterial culture capable of expressing heterologous protein |
| US4425437A (en) | 1979-11-05 | 1984-01-10 | Genentech, Inc. | Microbial polypeptide expression vehicle |
| US4338397A (en) | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
| US5360897A (en) | 1981-08-31 | 1994-11-01 | The University Of Rochester | Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
| US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US5100792A (en) | 1984-11-13 | 1992-03-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues |
| US4631211A (en) | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
| US4663161A (en) | 1985-04-22 | 1987-05-05 | Mannino Raphael J | Liposome methods and compositions |
| US4871488A (en) | 1985-04-22 | 1989-10-03 | Albany Medical College Of Union University | Reconstituting viral glycoproteins into large phospholipid vesicles |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| CA1338800C (en) | 1986-06-17 | 1996-12-17 | Michael Houghton | Hepatitis delta and diagnostics and vaccines |
| US5135855A (en) | 1986-09-03 | 1992-08-04 | The United States Of America As Represented By The Department Of Health And Human Services | Rapid, versatile and simple system for expressing genes in eukaryotic cells |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| DE10399031I1 (de) | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
| US5179022A (en) | 1988-02-29 | 1993-01-12 | E. I. Du Pont De Nemours & Co. | Biolistic apparatus for delivering substances into cells and tissues in a non-lethal manner |
| CA1324969C (en) | 1988-05-06 | 1993-12-07 | Jeffrey R. Shuster | High level expression of proteins in yeast |
| AU631377B2 (en) | 1988-08-25 | 1992-11-26 | Liposome Company, Inc., The | Affinity associated vaccine |
| DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
| US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
| ES2055785T3 (es) | 1989-01-17 | 1994-09-01 | Eniricerche Spa | Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas. |
| CA2357538A1 (en) | 1989-03-21 | 1990-10-04 | Wisconsin Alumni Research Foundation | Expression of exogenous polynucleotide sequences in a vertebrate |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| FI920131A0 (fi) | 1989-07-14 | 1992-01-13 | Praxis Biolog Inc | Cytokin- och hormonbaerare foer konjugatvaccin. |
| US6572862B1 (en) | 1989-11-08 | 2003-06-03 | Baylor College Of Medicine | Methods and reagents to detect and characterize Norwalk and related viruses |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| FR2658432B1 (fr) | 1990-02-22 | 1994-07-01 | Medgenix Group Sa | Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation. |
| GB2276169A (en) | 1990-07-05 | 1994-09-21 | Celltech Ltd | Antibodies specific for carcinoembryonic antigen |
| WO1992001070A1 (en) | 1990-07-09 | 1992-01-23 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
| DE69113564T2 (de) | 1990-08-13 | 1996-05-30 | American Cyanamid Co | Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff. |
| MY109299A (en) | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
| US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| CA2115742A1 (en) | 1991-08-20 | 1993-03-04 | Ronald G. Crystal | Adenovirus mediated transfer of genes to the gastrointestinal tract |
| US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| AU3630093A (en) | 1992-03-02 | 1993-10-05 | Biocine S.P.A. | Helicobacter pylori proteins useful for vaccines and diagnostics |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| EP0671948B1 (en) | 1992-06-25 | 1997-08-13 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine composition containing adjuvants |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| JPH08500250A (ja) | 1992-09-07 | 1996-01-16 | ベイラー・カレッジ・オブ・メディシン | ノーウォークおよび関連ウイルスを検出し、かつ特徴付けるための方法並びに試薬 |
| US5831005A (en) | 1992-09-24 | 1998-11-03 | Chiron Corporation | Synthesis of N-substituted oligomers |
| US5877278A (en) | 1992-09-24 | 1999-03-02 | Chiron Corporation | Synthesis of N-substituted oligomers |
| US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
| ES2109685T5 (es) | 1993-03-23 | 2005-09-01 | Smithkline Beecham Biologicals S.A. | Composiciones para vacunas que contienen monofosforil-lipido a 3-o-desacilado. |
| US5591601A (en) | 1993-05-14 | 1997-01-07 | Ohio University Edison Animal Biotechnology Institute | DNA polymerase gene expression system utilizing an RNA polymerase co-delivered with the gene expression vector system |
| BR9407035A (pt) * | 1993-06-29 | 1996-03-12 | Chiron Corp | Fragmento de fator de crescimento de queratinócitos conjugado composição terapêutica molécula de DNA vetor de expressão célula hospedeira processo para produzir fragmento de fator de crescimento de queratinócitos processo para cicatrização de ferimento e processo de tratamento de doença hiperproliferativa da epiderme |
| ATE195735T1 (de) | 1993-07-15 | 2000-09-15 | Minnesota Mining & Mfg | Imidazo (4,5-c)pyridin-4-amine |
| US5834441A (en) | 1993-09-13 | 1998-11-10 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Adeno-associated viral (AAV) liposomes and methods related thereto |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| ES2235176T3 (es) * | 1994-10-24 | 2005-07-01 | THE TEXAS A & M UNIVERSITY SYSTEM | Inmunizacion oral con plantas transgenicas. |
| US5676950A (en) | 1994-10-28 | 1997-10-14 | University Of Florida | Enterically administered recombinant poxvirus vaccines |
| WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
| IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| JP2000511769A (ja) | 1996-04-02 | 2000-09-12 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
| JP2000512487A (ja) | 1996-05-14 | 2000-09-26 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
| ES2251028T3 (es) | 1996-05-24 | 2006-04-16 | Chiron Corporation | Proteina de fusion de epitopos multiples. |
| US6514731B1 (en) | 1996-05-24 | 2003-02-04 | Chiron Corporation | Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens |
| DE19630390A1 (de) | 1996-07-26 | 1998-01-29 | Chiron Behring Gmbh & Co | Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung |
| CA2639051A1 (en) | 1996-09-04 | 1998-03-12 | Takara Bio Inc. | Fungal antigens and process for producing the same |
| US6403098B1 (en) | 1996-09-26 | 2002-06-11 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| US6616931B1 (en) | 1996-09-26 | 2003-09-09 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| EP0942983B2 (en) | 1996-10-31 | 2014-09-10 | Human Genome Sciences, Inc. | Streptococcus pneumoniae antigens and vaccines |
| EP2172216A3 (en) | 1997-03-10 | 2010-11-24 | Ottawa Hospital Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
| US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| US6800744B1 (en) | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
| US6348450B1 (en) | 1997-08-13 | 2002-02-19 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom and uses thereof |
| DE69838992T2 (de) | 1997-09-05 | 2008-12-24 | Glaxosmithkline Biologicals S.A., Rixensart | Öl-in-Wasser Emulsionen mit Saponinen |
| US6756361B1 (en) | 1997-10-14 | 2004-06-29 | Nabi | Enterococcus antigens and vaccines |
| CA2671261A1 (en) | 1997-11-06 | 1999-05-20 | Novartis Vaccines And Diagnostics S.R.L. | Neisserial antigens |
| AU762606B2 (en) | 1997-11-21 | 2003-06-26 | Genset S.A. | Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
| WO1999028475A2 (en) | 1997-11-28 | 1999-06-10 | Genset | Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
| GB9725084D0 (en) * | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| HUP0101139A3 (en) | 1997-12-02 | 2003-11-28 | Powderject Vaccines Inc Madiso | Transdermal delivery of particulate vaccine compositions |
| BR9906927A (pt) | 1998-01-14 | 2001-11-20 | Chiron Spa | Proteìnas de neisseria meningitidis |
| GB9807721D0 (en) | 1998-04-08 | 1998-06-10 | Chiron Spa | Antigen |
| WO1999052549A1 (en) | 1998-04-09 | 1999-10-21 | Smithkline Beecham Biologicals S.A. | Adjuvant compositions |
| NZ532665A (en) | 1998-05-01 | 2005-11-25 | Inst Genomic Research | Neisseria meningitidis antigens and compositions |
| GB9810193D0 (en) | 1998-05-12 | 1998-07-08 | Smithkline Beecham Biolog | Novel compounds |
| US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| EP1105495B2 (en) | 1998-08-14 | 2009-01-21 | Novartis Vaccines and Diagnostics, Inc. | Method for producing yeast expressed hpv types 6 and 16 capsid proteins |
| GB9819898D0 (en) | 1998-09-11 | 1998-11-04 | Smithkline Beecham Plc | New vaccine and method of use |
| AU1202200A (en) | 1998-10-09 | 2000-05-01 | Chiron Corporation | Neisseria genomic sequences and methods of their use |
| DK1126876T3 (da) | 1998-10-16 | 2007-07-02 | Glaxosmithkline Biolog Sa | Adjuvanssystemer og vacciner |
| US6589529B1 (en) | 1998-10-30 | 2003-07-08 | Children's Hospital Medical Center | Rotavirus subunit vaccine |
| AU1722300A (en) | 1998-11-12 | 2000-05-29 | Regents Of The University Of California, The | Chlamydia pneumoniae genome sequence |
| GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
| CA2357004A1 (en) * | 1998-12-23 | 2000-06-29 | Boyce Thompson Institute For Plant Research | Expression of immunogenic hepatitis b surface antigens in transgenic plants |
| AU2868200A (en) | 1999-02-08 | 2000-08-25 | Chiron Corporation | Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo |
| IL145043A0 (en) | 1999-03-19 | 2002-06-30 | Smithkline Beecham Biolog | Vaccine |
| JP2002541808A (ja) | 1999-04-09 | 2002-12-10 | テクラブ， インコーポレイテッド | ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア |
| AU4366000A (en) | 1999-04-14 | 2000-11-14 | Chiron Corporation | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
| WO2000067161A2 (en) | 1999-05-04 | 2000-11-09 | Grant Lee H | Method and apparatus for categorizing and retrieving network pages and sites |
| KR100771402B1 (ko) | 1999-06-22 | 2007-10-30 | 국립감염증연구소장이 대표하는 일본국 | Ｓｒｓｖ 검출 킷트 |
| MY133158A (en) | 1999-08-17 | 2007-10-31 | Smithkline Beecham Biologicals S A | Vaccine |
| CA2383110A1 (en) | 1999-09-24 | 2001-03-29 | Veronique Henderickx | Adjuvant comprising a polyoxyethylene alkyl ether or ester and at least one non-ionic surfactant |
| EP1221971A2 (en) | 1999-09-24 | 2002-07-17 | SmithKline Beecham Biologics SA | Use of the combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
| CN102172398A (zh) | 2000-01-17 | 2011-09-07 | 诺华疫苗和诊断有限公司 | 含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗 |
| US20010044416A1 (en) | 2000-01-20 | 2001-11-22 | Mccluskie Michael J. | Immunostimulatory nucleic acids for inducing a Th2 immune response |
| AU2001249380A1 (en) | 2000-03-22 | 2001-11-07 | Chiron Corporation | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| DE60125240T3 (de) | 2000-06-15 | 2010-10-28 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Hcv-antigen/antikörper-kombinations-assay |
| CA2414884A1 (en) | 2000-07-03 | 2002-01-10 | Chiron S.P.A. | Immunisation against chlamydia pneumoniae |
| JP2002020399A (ja) | 2000-07-10 | 2002-01-23 | Osaka Prefecture | ノルウォークウイルス（ｎｖ）を認識するモノクローナル抗体 |
| AU8743001A (en) | 2000-08-28 | 2002-03-13 | Aventis Pasteur | Moraxella polypeptides and corresponding dna fragments and uses thereof |
| CA2423487C (en) | 2000-09-26 | 2015-12-15 | Hybridon, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| IL154853A0 (en) | 2000-10-27 | 2003-10-31 | Chiron Spa | Nucleic acids and proteins from streptococcus groups a & b |
| AU2002220025A1 (en) | 2000-11-03 | 2002-05-15 | Baylor College Of Medicine | Rotavirus enterotoxin NSP4 and methods of using same |
| WO2002080982A2 (en) | 2001-01-12 | 2002-10-17 | Chiron Corporation | Nucleic acid mucosal immunization |
| GB0103424D0 (en) | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
| EP1372708B1 (en) | 2001-02-13 | 2008-06-18 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY | Vaccine for transcutaneous immunization against travellers' diarrhoea |
| CA2441530A1 (en) | 2001-03-19 | 2002-09-26 | Iomai Corporation | Transcutaneous immunostimulation |
| EP1399181B1 (en) | 2001-05-18 | 2012-05-09 | The Government of the USA, as represented by the Secretary, Dept. of Health and Human Services, Centers for Disease Control and Prevention | Peptide vaccines against group a streptococci |
| EP2332573A1 (en) | 2001-05-31 | 2011-06-15 | Novartis Vaccines and Diagnostics, Inc. | Chimeric alphavirus replicon particles |
| CA2492823A1 (en) | 2001-09-14 | 2003-03-27 | Martin F. Bachmann | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| EP2196217A1 (en) | 2001-09-14 | 2010-06-16 | Cytos Biotechnology AG | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
| GB0123580D0 (en) | 2001-10-01 | 2001-11-21 | Glaxosmithkline Biolog Sa | Vaccine |
| US6942965B2 (en) * | 2001-10-12 | 2005-09-13 | Chiron Corporation | Hepatitis A virus nucleotide sequences, recombinant proteins and uses thereof |
| WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| JP4413617B2 (ja) | 2001-12-12 | 2010-02-10 | カイロン ソチエタ ア レスポンサビリタ リミタータ | Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫化 |
| GB0203403D0 (en) | 2002-02-13 | 2002-04-03 | Chiron Spa | Chlamydia cytotoxic-T cell epitopes |
| WO2003072716A2 (en) | 2002-02-27 | 2003-09-04 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services | Sequence analysis of the tetravalent rotavirus vaccine |
| GB0210128D0 (en) | 2002-05-02 | 2002-06-12 | Chiron Spa | Nucleic acids and proteins from streptococcus groups A & B |
| WO2004041157A2 (en) | 2002-09-13 | 2004-05-21 | Chiron Corporation | Group b streptococcus vaccine |
| WO2004060308A2 (en) | 2002-12-27 | 2004-07-22 | Chiron Corporation | Thiosemicarbazones as anti-virals and immunopotentiators |
| WO2004064759A2 (en) | 2003-01-21 | 2004-08-05 | Chiron Corporation | Use of tryptanthrin compounds for immune potentiation |
| CA2522379C (en) | 2003-04-10 | 2012-10-23 | Chiron Corporation | The severe acute respiratory syndrome coronavirus |
| US20100255002A1 (en) | 2003-06-26 | 2010-10-07 | Chiron Corporation | Immunogenic compositions for chlamydia trachomatis |
| WO2005032457A2 (en) | 2003-07-21 | 2005-04-14 | Boyce Thompson Institute For Plant Research, Inc. | Vectors and methods for immunization against norwalk virus using transgenic plants |
| WO2005032582A2 (en) | 2003-07-31 | 2005-04-14 | Chiron Corporation | Immunogenic compositions for streptococcus pyogenes |
| KR20060126917A (ko) | 2003-09-02 | 2006-12-11 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
| JP2007537137A (ja) | 2003-09-24 | 2007-12-20 | モンタナ ステート ユニバーシティ | ノロウィルスモノクローナル抗体及びペプチド |
| JP2007537757A (ja) * | 2004-05-17 | 2007-12-27 | カイロン コーポレーション | 切断ｃ型肝炎ｎｓ５ドメインおよびこれを含む融合タンパク質 |
| CA2630220C (en) | 2005-11-22 | 2020-10-13 | Doris Coit | Norovirus and sapovirus antigens |
-
2006
- 2006-11-22 CA CA2630220A patent/CA2630220C/en active Active
- 2006-11-22 EP EP06849211A patent/EP1969001A2/en not_active Ceased
- 2006-11-22 AU AU2006335256A patent/AU2006335256B2/en active Active
- 2006-11-22 ES ES10192453.8T patent/ES2514316T3/es active Active
- 2006-11-22 EP EP10192453.8A patent/EP2360175B1/en active Active
- 2006-11-22 US US11/603,913 patent/US7527801B2/en active Active
- 2006-11-22 WO PCT/US2006/045280 patent/WO2007081447A2/en not_active Ceased
- 2006-11-22 JP JP2008542449A patent/JP5215865B2/ja active Active
-
2009
- 2009-03-24 US US12/383,420 patent/US8124104B2/en active Active
- 2009-03-24 US US12/383,425 patent/US8142793B2/en active Active
- 2009-03-24 US US12/383,419 patent/US8119145B2/en active Active
-
2010
- 2010-12-10 US US12/965,344 patent/US20110104192A1/en not_active Abandoned
-
2012
- 2012-01-20 US US13/355,192 patent/US20120141529A1/en not_active Abandoned
- 2012-11-27 US US13/686,837 patent/US9428739B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009516529A5 (enExample) | ||
| TWI479022B (zh) | 諾羅病毒衣殼與輪狀病毒ｖｐ６蛋白質做為組合疫苗的用途 | |
| Chung et al. | Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge | |
| CN108624601B (zh) | 酵母表达的柯萨奇病毒a10病毒样颗粒及其应用 | |
| CN107384944B (zh) | 酵母表达的柯萨奇病毒a6病毒样颗粒及其应用 | |
| Nicollier-Jamot et al. | Recombinant virus-like particles of a norovirus (genogroup II strain) administered intranasally and orally with mucosal adjuvants LT and LT (R192G) in BALB/c mice induce specific humoral and cellular Th1/Th2-like immune responses | |
| JP4769481B2 (ja) | ポリ−γ−グルタミン酸含有免疫補強剤組成物 | |
| JP2011506433A5 (enExample) | ||
| JP2006504644A5 (enExample) | ||
| JP6958818B2 (ja) | ヒトパピローマウイルスタイプ５８のｌ１タンパク質の突然変異 | |
| JP2010263899A (ja) | Ｌ２ペプチドを含むキメラ・ヒト・パピローマウイルス１６ｌ１タンパク質、それから調製したウイルス様粒子および該粒子の調製方法 | |
| Huo et al. | Hepatitis B virus core particles containing multiple epitopes confer protection against enterovirus 71 and coxsackievirus A16 infection in mice | |
| CN102559615A (zh) | Ev71疫苗制备方法及通过该方法制备的疫苗 | |
| AU674983B2 (en) | Vaccine compositions | |
| Li et al. | Enhancing humoral and mucosal immune response of PED vaccine candidate by fusing S1 protein to nanoparticle multimerization | |
| US20190247488A1 (en) | Expression cassettes and methods for obtaining enterovirus virus-like particles | |
| Chen et al. | Recombinant bacteriophage T4 displaying key epitopes of the foot-and-mouth disease virus as a novel nanoparticle vaccine | |
| CN107557347B (zh) | 肠道病毒71型的新型病毒样颗粒、其制备方法及应用 | |
| CN104479028B (zh) | 牛轮状病毒vp8*亚单位重组嵌合蛋白及其应用 | |
| CN115850398B (zh) | 新型冠状病毒奥密克戎系列变异株的多肽组合物及其应用 | |
| CN101085347B (zh) | 甲型肝炎-乙型肝炎-戊型肝炎联合疫苗 | |
| CN103189386B (zh) | 重组人类免疫缺陷病毒（hiv）包膜抗原蛋白和含其的疫苗 | |
| CN101564533B (zh) | 戊型肝炎蛋白-核酸复合疫苗及其制备方法 | |
| KR20240011134A (ko) | Rsv 및 piv3 감염을 예방하기 위한 조성물 및 방법 | |
| WO2006028214A1 (ja) | 経口投与ワクチン |